KM Research Hub
← 返回论文库
已完成 入排:排除 图源:可得 入排置信度 0.98

Long-Term Tofersen in SOD1 Amyotrophic Lateral Sclerosis.

Timothy M Miller, Merit E Cudkowicz, Pamela J Shaw, Angela Genge, Gen Sobue, Robert C Bucelli, Adriano Chiò, Philip Van Damme, Albert C Ludolph, Jonathan D Glass, Jinsy A Andrews, Suma Babu, Michael Benatar, Christopher J McDermott, François Salachas, Gaëlle Bruneteau, Ammar Al-Chalabi, Matthew Amorin, Ivan Nestorov, Danielle Graham, Luan Lin, Peng Sun, Manjit McNeill, Sohail Malek, Jennifer Inra, Steve Garafalo, Stephanie Fradette, VALOR and OLE Working Group

JAMA Neurol 83(2) 115-125

PMID41661214
PMCIDPMC12723595
DOI10.1001/jamaneurol.2025.4946
发表日期2026-02-09
入排依据:未发现恶性肿瘤人群证据。
摘要

摘要

IMPORTANCE: Approximately 2% of amyotrophic lateral sclerosis (ALS) cases are attributable to a pathogenic variant in the superoxide dismutase 1 (SOD1) gene. Tofersen, an intrathecal antisense oligonucleotide designed to reduce SOD1 protein synthesis, is the first and only approved therapy for the treatment of ALS in adults who have a variant in the SOD1 gene. OBJECTIVE: To evaluate the long-term effects of tofersen in adults with SOD1-ALS. DESIGN, SETTING, AND PARTICIPANTS: The phase 3, randomized, double-blind, placebo-controlled VALOR trial (A Study to Evaluate Efficacy, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tofersen in SOD1-ALS; conducted from March 2019 to July 2021) evaluated tofersen use over 28 weeks in adults (18 years and older) with weaknesses attributable to ALS and a confirmed SOD1 pathogenic variant at 32 sites in 10 countries; participants could then enroll in an open-label extension (OLE; completed August 2024). INTERVENTION AND EXPOSURE: Adults with SOD1-ALS were randomly assigned 2:1 to receive tofersen (100 mg) or placebo over a 24-week period in the VALOR study. All participants in the OLE were treated with tofersen. MAIN OUTCOMES AND MEASURES: Integrated analysis of VALOR and the OLE study aimed to compare early start vs placebo/delayed start (approximately 6 months later) treatment with tofersen. Key efficacy end points included measures of axonal injury and neurodegeneration (neurofilament), function and strength, quality of life, and survival. RESULTS: VALOR enrolled 108 participants with 42 unique SOD1 pathogenic variants (mean [SD] age: placebo/delayed-start group 51.2 [11.6] [n = 36]; early-start group: 48.1 [12.6] [n = 72]) with 19 (53%) and 43 (60%) of participants being male in the placebo/delayed- and early-start groups, respectively. Overall, 95/108 participants (88%) enrolled in the OLE, and 46 participants completed the OLE (early-start group, 34 [47%]; placebo/delayed-start group, 12 [33%]). At OLE completion, participants could have accumulated 3.5 years or more (range, 192-276 weeks) of follow-up from the start of VALOR. Over 148 weeks, earlier initiation of tofersen (compared to later initiation) was associated with numerically less decline in measures of clinical function (Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised score, -9.9 vs -13.5 points), respiratory function (slow vital capacity, -13.8% vs -18.1%), muscle strength (handheld dynamometry megascore, -0.38 vs -0.43 points), and quality of life (Amyotrophic Lateral Sclerosis Assessment Questionnaire 5 score, 17.0 vs 22.5 points; EuroQol 5 Dimension, 5 Level Questionnaire score, -0.1 vs -0.2 points). Tofersen prolonged survival relative to the expected natural history of SOD1-ALS. Most adverse events were consistent with ALS progression or known procedural adverse effects. All serious neurological adverse events were reversible; few led to tofersen discontinuation. CONCLUSIONS AND RELEVANCE: Final data from VALOR and the OLE demonstrated the benefit of tofersen in SOD1-ALS and provide clear rationale for its use in this population. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: VALOR NCT02623699; OLE NCT03070119.

KM 提取结果

1 个 Figure · 3 个 KM 面板

进入结果中心
KM Figure3 个面板

Figure 2

Figure 2.. Time to Death or Permanent Ventilation Baseline plasma neurofilament light chain (NfL) was < 75.6 pg/mL in the slower-progressing subgroup and ≥75.6 pg/mL in the faster-progressing subgroup. Time to death or permanent ventilation was defined as the time from first dose to death or permanent ventilation (≥22 hours of mechanical ventilation [invasive or noninvasive] per day for ≥21 consecutive days), whichever came first. Participants who did not meet the end point definition were censored at the last known date they were alive. Only events that were adjudicated by the end point adjudication committee were included. Cross marks indicate censored observations. The dotted line corresponds to week 192, the time point when the last participant enrolled reached the end of the study. ITT indicates intention-to-treat.

A

Time to Death or Permanent Ventilation

Figure 2 · Panel A

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel A 是同一 Figure 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线 2:short span
查看结果
B

Time to Death or Permanent Ventilation

Figure 2 · Panel B

quality_warning 待 EXE 对齐 预期 2 条 已提取 1 条

Panel B 是同一 Figure 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似重复轨迹:同一条 KM 曲线可能被重复识别疑似图例或人工水平线:轨迹出现不合理的共同平台曲线缺失:预期 2 条,实际恢复 1 条疑似重复轨迹:同一条 KM 曲线可能被重复识别
查看结果
C

Time to Death or Permanent Ventilation

Figure 2 · Panel C

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel C 是同一 Figure 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似图例或人工水平线:轨迹出现不合理的共同平台疑似图例或人工水平线:轨迹出现不合理的共同平台曲线 2:off origin start
查看结果
其他 Figure(1,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 1Figure 1.. Change in Outcomes From Baseline to Week 148 Error bars represent 95% CIs (A) or standard errors (B, C and D). Missing data were handled using multiple imputation. ALSFRS-R indicates Amyotrophic Lateral Sclerosis Functional Rating Scale–Revised; HHD, handheld dynamometry; LS, least squares; NfL, neurofilament light chain; OLE, open-label extension; SVC, slow vital capacity.
非 KM Figure